The AI and memory-chip rallies may have already minted their biggest winners, but biotech is mounting a breakout of its own, with the XBI biotech ETF sharply outperforming the broader market as cash-rich drugmakers race to buy promising pipelines before blockbuster patent losses begin eroding reven…
AtaiBeckley Inc. (NASDAQ:ATAI) agreed to be bought by Eli Lilly for $6.75 cash plus up to $2.50 in milestone CVRs as its lead intranasal antidepressant BPL‑003—now in Phase 3 after FDA Breakthrough status—advances while the company weighs sales or partnerships and sees a cut in analyst target to $7…
Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:HELP) (Cboe…
AtaiBeckley entered into a definitive merger agreement for its acquisition by Eli Lilly, offering $6.75 per share in cash plus a contingent value right of up to $2.50 per share based on clinical and regulatory milestones. The deal will be executed via a merger of Lilly subsidiary Albali Acquisition…
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depressionAcquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental healthINDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and C…
Shares of AtaiBeckley Inc (ATAI) jumped 59% after-hours following reports that pharmaceutical giant Eli Lilly is close to a deal for the psychedelic drug developer.Eli Lilly (LLY) is nearing an agreement involving AtaiBeckley, Bloomberg reported on Wednesday, citing people familiar with the matter…
(15:48 GMT) ATAI Life Sciences Price Target Maintained With a $10.00/Share by Jefferies
NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. NASDAQ:ATAI (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient…
